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The nm23 gene is a putative metastasis-suppressor gene originally
identified by screening of cDNA libraries from murine melanoma
cell sublines of varying metastatic potential (Steeg et al, 1988).
Several evidences in favour of its metastasis suppressor capacity
have been reported. A decrease in nm23-H1 RNA was observed in
highly metastatic tumour cells from various rodent systems
(Bevilacqua et al, 1989) and transfection of the nm23-H1 cDNA in
murine melanoma and human breast cancer cells was shown to
cause a reduction in cell migration in response to serum and
defined growth factors in vitro and a reduction of tumour
metastatic potental in vivo (Leone et al, 1991a).
The two highly homologous nm23 genes NME1 and NME2 are
located in a tandem array 4 kb apart on the long arm of chromo-
some 17 (region 17q21.3) (Gilles et al, 1991), a region which is
frequently deleted in cancer. NME1 and NME2 code for the
proteins Nm23-H1 and Nm23-H2 respectively, of approximately
17 kDa each, which display an 88% amino acid homology
between each other. It has been reported that these two proteins
correspond to both chains of the nucleoside diphosphate kinase
from human erythrocytes, (NDPK)A and (NDPK)B respectively
(Gilles et al, 1991; Stahl et al, 1991).
nm23 seems to play an important role in human tumorigenesis,
which has not been clearly defined up to now. Although Nm23
proteins have been demonstrated to have NDPK activity, both its
precise function and the mechanism by which it supposedly partic-
ipates in anti-metastatic protection in human tumours is still uncer-
tain and controversial, since it has not been established whether
the enzyme activity itself mediates the biological effect of nm23 in
tumours or not. Potential roles for the Nm23 protein have been
suggested, such as in the formation of a basement membrane
(Howlett et al, 1994) tumour differentiation (Lombardi et al, 1995)
and cell proliferation (Caligo et al, 1995).
Despite the high degree of homology between Nm23-H1 and
Nm23-H2 proteins, they seem to have different functions. Nm23-
H2 has been proposed as a co-factor, modulating the transcrip-
tional activity of certain promoters, since it contains a putative
leucine zipper motif in its sequence which shows high homology
with purine binding factor (PuF), which has been shown to initiate
transcription of the c-myc gene in vitro (Postel et al, 1993), with
the I-factor, the ‘differentiation inhibiting factor’, purified from
mouse myeloid leukaemia cells, which suppresses differentiation
of leukaemic cells (Okabe-Kado et al, 1992) and with the neuro-
blastoma p19 protein (Hailat et al, 1991). Therefore, Nm23-H2
might be more involved in proliferation, and not in metastasis.
Loss of heterozygosity and/or reduced expression of nm23 has
been correlated with worse prognosis and increased incidence of
metastasis in many human tumours, such as breast carcinoma
(Bevilacqua et al, 1989; Hennessy et al, 1991; Royds et al, 1993),
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malignant melanoma (Florenes et al, 1992), gastric cancer
(Nakayama et al, 1993) and hepatocellular carcinoma (Nakayama
et al, 1992), a finding that would agree with its putative role as a
metastasis-suppressing or, more generally, as a tumour suppressor
gene. On the other hand, however, we have that nm23-overexpres-
sion has been correlated with metastatic spread, progression and
tumour aggressiveness in pancreatic carcinoma (Nakamori et al,
1993), lung adenocarcinoma (Ozeki et al, 1994), neuroblastoma
(Hailat et al, 1991; Leone et al, 1993), colon carcinoma (Royds,
1994), and ovarian carcinoma (Mandai et al, 1994, 1995). A lack
of correlation between NDP kinase expression and lymph node
metastasis in breast carcinoma has also been suggested (Sastre-
Garau et al, 1992). Moreover, in neuroblastoma, elevated levels of
nm23 transcripts along with amplification and mutation of the
nm23-H1 gene are associated with advanced stages of the disease
and poor patient survival (Hailat et al, 1991; Leone et al, 1993;
Chang et al, 1994). Therefore, it might be that nm23 plays a tissue-
specific role and that different regulatory mechanisms may act
depending on the kind of tumour.
Somatic allelic deletions of nm23-H1 have been studied in
human cancers, such as breast, kidney, colon and lung (Leone et al,
1991b). Although in some of these cases somatic allelic deletions
seem to correlate with an increased incidence of metastasis, it has
not been possible to determine yet if this increase is actually
related to the loss of nm23. Mutations and/or genetic alterations of
the nm23-H1 gene, together with overexpression associated with a
more malignant phenotype have also been found in some human
tumours, like aggressive childhood neuroblastomas (Leone et al,
1993).
The role that the nm23-H1 gene might play in ovarian carci-
noma has not been conclusively established up to now (Mandai et
al, 1994, 1995; Scambia et al, 1996; Schneider et al, 1996). It has
been reported by Mandai et al (1994) that ovarian cancer patients
with metastatic lymph node involvement have lower nm23 levels
than lymph node-negative cases, and by Kapitanovic et al (1995)
that metastatic ovarian carcinomas were more frequently negative
for nm23-H1 than non-metastatic ones. Mandai et al (1994) also
studied the expression of both nm23-H1 and nm23-H2 in ovarian
tumours and found significantly higher levels of mRNA in carci-
noma tissues, compared with benign tumours. This was confirmed
recently by us, who studied nm23 expression in ovarian cancer by
means of immunohistochemistry in a small, pilot study, and found
that most invasive, advanced-stage tumours overexpressed nm23-
H1, whereas low-malignant-potential stage I ovarian tumours did
so significantly less (Schneider et al, 1996).
We devised the present study in order to determine whether 
the changes in nm23 expression influence prognosis and are
associated with genetic alterations.
MATERIALS AND METHODS
Patients and tumours
We studied 247 epithelial ovarian carcinoma samples from
Universitäts-Frauenlink Göttingen, Germany, Universidad del País
Vasco, Bilbao, Spain, and German Cancer Research Center,
Heidelberg, Germany, belonging to patients treated between 1982
and 1994.
All patients were submitted initially to a complete staging
laparotomy. Lymphadenectomy was not routinely performed in
advanced stages, since it would not alter the final staging (tumour
masses above 2 cm in diameter define the same IIIC stage as posi-
tive retroperitoneal nodes), and thus would not influence the kind
of adjuvant treatment. It was limited to apparent early stages, to
confirm that they were not occult surgical stage IIIC. The archival
pathologic specimens of this initial laparotomy yielded the tumour
material for the present study.
The histology of the tumours was as follows: 102 (41.3%)
serous-papillary; 47 (19.0%) endometrioid; 37 (15.0%) mucinous;
48 (19.4%) undifferentiated; 12 (4.9%) clear cell; 1 (0.4%) mixed-
epithelial.
Staging of the patients was performed according to the classifi-
cation of the International Federation of Obstetrics and
Gynaecology (FIGO). The distribution by surgical stage was: 28
(11.3%) stage I; 29 (11.7%) stage II; 144 (58.4%) stage III; 46
(18.6%) stage IV.
From surgical stage IG3 upwards, all patients received plat-
inum-based adjuvant chemotherapy, which was maintained for a
minimum of 6 cycles if their status allowed it, or if there was no
clinically evident tumour progression after the first three cycles of
treatment.
Immunohistochemistry was performed on 247 ovarian tumours.
Sixty samples were also studied for mutations in the nm23-H1
gene by means of polymerase chain reaction single-strand
conformational polymorphism (PCR-SSCP) analysis and direct
sequencing.
Immunohistochemistry
Expression of the nm23-H1 gene was analysed by means of
immunohistochemistry in all 247 tumour samples, looking for the
typical cytoplasmic reaction described in previous cellular local-
ization studies.
The immunohistochemical technique was the same described
extensively by us in a previous pilot study on nm23 expression in
ovarian tumours (Schneider et al, 1996). Briefly, the procedure
was carried out on 5 mm sections from routinely processed,
formalin-fixed, paraffin-embedded tumour blocks. The technique
itself was a variant of the usual streptavidin–biotin–peroxidase
method previously described by us for fresh-frozen tissue
(Schneider et al, 1994a). To ensure uniformity of results we used 
a commercial streptavidin–biotin–peroxidase kit (Histostain-SP,
Zymed, San Francisco. CA, USA) throughout the whole proce-
dure, which was entirely carried out at room temperature. As posi-
tive controls we used slides from mammary carcinomas known to
express high levels of nm23. The monoclonal antibody used was
NCL-nm23, manufactured by Novocastra Ltd (Newcastle, UK).
NCL-nm23 recognizes the nm23-H1 protein, with a reported
slight cross-reactivity for nm23-H2.
The slides were dewaxed in xylene, and then rehydrated in
descending concentrations of alcohol (100%, 96% and then 
70%) and finally 10 min in phosphate-buffered saline (PBS).
Afterwards, the preparations were incubated with blocking serum
for 10 min, and subsequently with the monoclonal antibody NCL-
nm23 diluted 1:100, for 1 hour in a humid chamber. They were
then washed in PBS three times for 3 min, after which the second
biotinylated-bridge-antibody was applied for 10 min. Following
three washes in PBS, 3 min each, the slides were incubated with
the streptavidin–peroxidase complex for 10 min, washed again
three times in PBS and stained with either diaminobenzidine or
aminoethyl carbazole for 3 min. They were then counterstained
with haematoxylin for 30 s, and mounted. Slides from each tumour1664 J Schneider et al
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were processed in parallel in identical fashion, but omitting the
monoclonal antibody and leaving them with the blocking serum
instead, and served as negative controls.
For the evaluation of the results of this study, we have adopted
the semiquantitative scale used previously by us (Schneider et al,
1994a, 1996) which takes into account both the strength of the
staining reaction, as well as the proportion of reactive tumour
cells. So, + stands for staining of lower intensity than the positive
control, and ++ for staining of equal or higher intensity than the
positive control. Isolated tumour cells or tumour cell groups,
comprising less than 10% of visible tumour cells were termed ‘a’,
with ‘b’ designating up to 50% reactive tumour cells, and ‘c’ very
numerous (50–100%) reactive cells. Finally, a numerical value
was attributed to each possible combination: ‘+a’ 1 point, ‘++a’ 2
points, ‘+b’ 3 points, ‘++b’ 4 points, ‘+c’ 5 points and finally
‘++c’ 6 points. In this way, statistical processing of the data is
made more easy and, taking into account the staining intensity and
the number of reactive cells, the figure obtained reflects in an
acceptable way the overall level of expression of the studied gene
in each particular tumour. An example of ‘++c’ staining (highest
score of 6 points) is given in Figure 1.
Analysis of mutations by PCR-SSCP
The open reading frame of nm23-H1 is composed of five exons,
displayed along a genomic DNA fragment of approximately 10 kb.
They were amplified by means of PCR and mutational analysis of
the gene was performed by means of SSCP in 60 ovarian tumours.
We employed a simplified, non-radioactive variant of the PCR-
SSCP technique previously described by us for determining p53
mutations in gynaecologic tumours (Schneider et al, 1994b). It is,
in its turn, a modification of a previously reported protocol
(Martínez et al, 1997) and is performed on 7.5 ´ 10 ´ 0.5 cm
non-denaturing polyacrylamide gels.
DNA was extracted both from fresh-frozen, or from paraffin-
embedded tissue samples as previously described (Schneider et al,
1994b). For the PCR amplification reaction we used the oligo-
nucleotide primers flanking each exon described by Bafico et al
(1993) with the annealing temperature being adjusted for each
primer pair (Table 1). The PCR reaction mix (25 ml) contained
approximately 100 ng DNA, 50 pmoles of each primer, 1.25 U Taq
polymerase, 100 mM of each deoxyribonucleoside triphosphate,
1.5 mM magnesium-chloride (MgCl2) 1 ´ reaction buffer and
ddH2O up to 25 ml. The three-step PCR was carried out for 30
cycles consisting of a denaturing step at 95°C for 1 min, followed
by 30 s at the optimal annealing temperature for each primer pair,
and 72°C for 30 s as final extension step. The obtained amplified
product was then denatured as follows:
1–1.5 ml of PCR-product were added to 7 ml of the denatural-
izing solution which contains 95% formamide, 20 mM EDTA,
0.05% bromophenol blue and 0.05% xylene cyanol. Afterwards
the mixture was heated to 95°C for 10 min, and then rapidly
AB
Figure 1 (A) Immunohistochemical detection of nm23-H1 expression. Strong staining in more than 50% of tumour cells. NCL-nm23 MAb,
streptavidin–biotin–peroxidase 3 250. (B) Negative control of (A)
Table 1 Primers used for amplification of exons 1 through 5 of the nm23 gene and amplification conditions employed
Exon Size Annealing Sequence
(bp) t (°C)
1 79 55 PU:5¢-GTCTGAAAAACGTAGCGCCGG-3¢
PD:5¢-CTTAGGTTTGAACTCCGGCTG-3¢
2 130 58 PU:5¢-GCTTGAGACGGATGACGCTGTA-3¢
PD:5¢-CAGGTTAATCACAGTGTTCTCC-3¢
3 101 58 PU:5¢-ATGTCCTTAGATGGTTTGGGGGT-3¢
PD:5¢-TTTGGTCTCATTCATGGCTGTAT-3¢
4 113 50 PU:5¢-GCCACATTTTCTGCTGTGATT-3¢
PD:5¢-CCCAAATCCTTGTGGCAACT-3¢
5 115 55 PU:5¢-GTCTAATGTCCATGGAGCTTC-3¢
PD:5¢-CAGATGGTCGGGGATGGTAAC-3¢nm23 expression in ovarian cancer 1665
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plunged into ice for at least 5 min, prior to loading it onto the elec-
trophoresis gel, which was a non-denaturing 15% polyacrylamide
minigel (7.5 ´ 10 ´ 0.5 cm) (acrylamide:bisacrylamide = 49:1).
The buffer chamber was filled with 0.5 ´ TBE buffer.
The wells were loaded with approximately 8 ml of the sample
mixture described above, and the gel was run in a Mini Protean
(BioRad) vertical electrophoretic chamber at 300–400 V  under
4°C refrigeration for 2–3 h, according to the specifications
displayed in Table 2, which varied for each exon, in order to opti-
mize the visualization of the bands. Finally, the gels were silver-
stained at room temperature: (i) 3 min incubation in 1% nitric acid
(HNO3); (ii) brief washing in distilled water; (iii) 25 min incuba-
tion, with gentle agitation, in 0.1% silver nitrate solution (AgNO3)
with 150 ml formaldehyde 37% per 100 ml solution; (iv) brief
washing in distilled water; (v) incubation in cold 3% NaCO3 solu-
tion with 150 ml formaldehyde 37% per 100 ml solution; the solu-
tion is discarded as soon as it blackens, and fresh solution is added
to repeat the procedure at least once again or until the bands appear
clearly in the gel; (vi) when the staining is considered optimal, the
reaction is stopped by incubating the gel in 10% acetic acid for
30 min; (vii) the gels can then be dessicated for permanent
storage.
Bands should be clearly visible, with low or absent background.
Mutations make themselves evident by a shift in the migration
pattern of the bands compared to the normal counterparts, an
aberrant number of bands, or a combination of both. Direct
sequencing of the amplified exons was performed using the ABI
Prism 377 DNA Sequencer by Perkin-Elmer, strictly following the
manufacturer’s protocol, using their reagents.
Statistical analysis
Time was calculated from the date of surgery to the date of either
death or last follow-up visit prior to closure of the study. It was
ensured that surviving patients were indeed alive at this time. If
this could not be done, the patients were included as ‘lost’
following their last visit. The median follow-up time for the whole
cohort (dead and surviving) was 27 months (range 1–171).
The association between survival and nm23 overexpression was
investigated using the Kaplan–Meier method and the log-rank test.
The prognostic importance of this variable was assessed in a Cox
proportional hazards regression analysis in the whole cohort, and
also separately in each stratum corresponding to the other predic-
tive variables identified in the univariate analysis. Finally, a multi-
variate model was fitted, including nm23 status and the rest of
variables proving to have an independent prognostic effect. In the
final model, we tested whether any interaction term involving
nm23 expression was statistically significant.
Implicit in Cox’s model is the assumption of proportional
hazards, namely, a stable prognostic effect over time. Given the
extensive follow-up of this study, we considered it important to
check if this condition was indeed true for the studied marker. 
For this purpose, crude and adjusted analyses were obtained at
different time intervals, as proposed by Breslow and Day (1987).
In addition, a graphical evaluation was carried out, by plotting the
cumulative hazard ratio along the follow-up period (Hess, 1995).
This parameter is a reasonable estimate of the hazard ratio and,
due to its greater stability, easier to plot on a graph. The graph
gives an intuitive image of the stability of the marker’s predictive
power over time.
Table 2 Predictors of survival in ovarian cancer according to the univariate analysis
No of No of % of Survival Hazard 95% Confidence P-value
patients deaths 12 months 36 months 60 months ratio interval
Age
< 60 102 74 79 55 36 1
60–70 66 53 70 35 27 1.43 1.00 2.03 0.048
³ 70 43 37 60 26 18 1.88 1.27 2.76 0.002
Unknown 36 25 78 38 22 1.48 0.93 2.34 0.096
Histologic type
Serous 102 81 72 37 23 1
Mucinous 37 23 73 57 42 0.58 0.36 0.92 0.021
Mixed-epithelial 1 1 100 100 0 —
Undifferentiated 48 38 75 39 24 0.93 0.64 1.37 0.730
Endometrioid 47 35 79 53 41 0.70 0.47 1.04 0.076
Clear cell 12 11 58 21 10 2.09 1.11 3.94 0.023
Surgical stage
I 28 9 89 81 73 1
II 29 15 93 72 58 1.69 0.74 3.86 0.215
III 144 122 71 36 20 5.17 2.59 10.31 <0.001
IV 46 43 59 20 11 7.67 3.68 15.99 <0.001
Grade of differentiation
Well 22 13 68 59 50 1
Moderate 47 29 89 61 52 1.00 0.52 1.93 0.995
Poor 147 125 69 34 19 2.08 1.17 3.70 0.013
Unknown 31 22 74 37 22 2.12 1.06 4.26 0.034
Index of Nm23-H1 expression
0–3 135 94 73 46 36 1
4–6 112 95 73 38 20 1.46 1.10 1.94 0.0101666 J Schneider et al
British Journal of Cancer (2000)  82(10), 1662–1670 © 2000 Cancer Research Campaign
As a last step, a multivariate model was used to evaluate a more
restricted and homogeneous set of cases, including only well or
moderately differentiated tumours corresponding to surgical stages
I and II.
RESULTS
Ovarian carcinoma samples from 247 patients were examined,
prior to any kind of chemotherapeutic or hormonal treatment, for
the expression of the nm23-H1 gene.
Mutations were studied by means of PCR-SSCP and direct
sequencing of the open reading frame of the gene, in a subset of 60
randomly chosen tumours.
In the univariate analysis (Table 2), the most discriminating cut-
off level was obtained for the group of tumours showing a strong
staining in more than 10% of cells (++b, +c or ++c, or with scores
4–6, according to our semiquantitative scale). When comparing
this group of patients to the rest, they showed a significantly worse
survival (Figure 2). The effect of nm23 overexpression on prog-
nosis, moreover, was maintained over the whole follow-up period
(Figure 3). The stratified univariate analysis, looking for prognos-
tically relevant associations between nm23 overexpression and
other predictive parameters (Table 3), seemed to indicate a strong
discriminating power of nm23 in the subgroup of well- and
moderately differentiated early (I & II) stage tumours. This was
confirmed by stratified life-table analysis (Figure 4), as well as by
multivariate analysis, which demonstrated that, in this subset of
patients with an inherent ‘better’ prognosis, the only independent
predictor of an ominous outcome was, indeed, nm23 overexpres-
sion (Table 5). In the complete multivariate model, contemplating
the whole cohort of patients, on the other hand (Table 4), the
predictive power of nm23 was overshadowed by the classically
known independent prognosticators: age > 60 years, advanced
surgical stage and poor degree of differentiation.
Mutation of the nm23 gene, as suggested by an abnormal band
pattern in the PCR-SSCP analysis, was detected in only one
tumour out of 60 analysed by this means. This mutation (a C to A
transversion) was located in the untranslated region within exon 1
of the nm23-H1 gene, 78 base pairs before the starting codon.
Therefore, it can be assumed that the negative impact on prognosis
of nm23 overexpression is most probably due to the effect of the
wild-type gene in our series of ovarian cancers, and not to mutated
variants of it.
DISCUSSION
The real function of the nm23-H1 gene in most human tumours is
still uncertain, and ovarian carcinoma is no exception in this
respect.
According to Mandai et al (1994), who were the first to study
nm23 expression in ovarian cancer by means of mRNA measure-
ments, overexpression of both nm23-H1 and nm23-H2 genes
seems to be associated with tumour progression, since there are
higher levels of expression in malignant tissue with respect to
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Figure 2 Life table analysis according to nm23 expression in epithelial
ovarian cancer. n = 247
Figure 3 Graphical representation of the cumulative hazard ratio of nm23
expression in epithelial ovarian cancer along the follow-up period. A constant
positive value represents a stable negative prognostic effect over timenm23 expression in ovarian cancer 1667
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normal ovary and benign tumours. This has been subsequently
confirmed by other studies (Leary et al, 1995; Schneider et al,
1996) with similar results using either Northern blotting or
immunohistochemistry. Although Mandai et al (1994) together
with Viel et al (1995) report that nm23 overexpression shows 
a significant association with more advanced tumour stages,
according to them it also seems to exert a suppressive action on the
development of lymph node metastasis. This apparently contradic-
tory finding is still devoid of a plausible explanation. Our study,
unfortunately, does not throw any additional light on this particular
point. As has been explained in Materials and Methods, we did not
routinely perform lymphadenectomies in advanced stages, for this
would have only increased the operative time and the surgical risk,
without influencing therapeutic decisions, according to our treat-
ment protocols.
Scambia et al (1996) showed an association of nm23-H1 over-
expression with both survival advantage and greater response to
chemotherapy in patients with advanced ovarian cancer, the
percentage of nm23-H1 positivity being higher in lymph node-
negative (70%) than in lymph node-positive cases (40%). They
studied 106 samples by immunohistochemistry and they found
that the survival rate of nm23-H1-positive cases was 50% versus
Table 3 Predictors of survival in ovarian cancer according to nm23-H1 expression; stratified analysis.
No of No of % Survival Hazard 95% Confidence P-value
patients deaths 12 months 36 months 60 months ratio interval
Age 0.347
< 60
nm23: 0–3 61 40 75 52 41 1
nm23: 4–6 41 34 85 59 29 1.29 0.81–2.03 0.282
60–70
nm23: 0–3 43 33 74 37 29 1
nm23: 4–6 23 20 61 30 21 1.29 0.74–2.25 0.375
³ 70
nm23: 0–3 22 17 59 41 31 1
nm23: 4–6 21 20 62 10 5 1.89 0.96–3.74 0.067
Unknown
nm23: 0–3 9 4 89 57 38 1
nm23: 4–6 27 21 74 33 18 2.32 0.79–6.84 0.126
Histologic type <0.001
Serous
nm23: 0–3 55 39 69 40 32 1
nm23: 4–6 47 42 74 33 12 1.42 0.92–2.20 0.115
Mucinous
nm23: 0–3 33 19 79 60 47 1
nm23: 4–6 4 4 25 25 – 4.60 1.50–14.11 0.008
Undifferentiated
nm23: 0–3 20 16 70 40 25 1
nm23: 4–6 28 22 79 38 23 1.13 0.59–2.15 0.716
Endometrioid
nm23: 0–3 23 16 83 48 39 1
nm23: 4–6 24 19 75 58 43 1.12 0.58–2.19 0.730
Clear cell
nm23: 0–3 4 4 50 25 25 1
nm23: 4–6 8 7 62 – – 1.07 0.27–4.21 0.921
Surgical stage 0.010
I
nm23: 0–3 22 7 95 86 75 1
nm23: 4–6 6 2 67 67 67 1.21 0.25–5.95 0.811
II
nm23: 0–3 20 8 90 70 70 1
nm23: 4–6 9 7 100 77 27 2.17 0.78–6.04 0.139
III
nm23: 0–3 70 57 69 33 21 1
nm23: 4–6 74 65 73 39 19 1.04 0.73–1.49 0.812
IV
nm23: 0–3 23 22 52 26 13 1
nm23: 4–6 23 21 65 13 9 1.13 0.61–2.06 0.701
Differentiation 0.001
Well or moderate
nm23: 0–3 52 28 85 65 59 1
nm23: 4–6 17 14 76 47 27 2.06 1.08–3.94 0.028
Poor
nm23: 0–3 75 62 64 62 20 1
nm23: 4–6 72 63 74 67 18 0.99 0.70–1.42 0.972
Unknown
nm23: 0–3 8 4 88 49 0 1
nm23: 4–6 23 18 70 33 22 1.56 0.52–4.69 0.4311668 J Schneider et al
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12% for nm23-H1-negative patients. These findings are
completely opposed to those reported by Mandai et al (1994), Viel
et al (1995) and ourselves. We already described in a previous pilot
study that nm23 expression, measured by means of immunohisto-
chemistry, seemed to be associated with tumour aggressiveness
and a trend towards lower survival (Schneider et al, 1996). This
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Figure 4 Life table analysis of the effect of nm23 expression in different subsets of patients, stratified by stage and differentiation of the tumours
Table 4 Predictors of survival in ovarian cancer according to the multivariate analysis
Results considering the whole Results considering only women with
cohort known age
Variable Hazard 95% Confidence Hazard 95% Confidence
ratio interval P-value ratio interval P-value
Differentiation & nm23 expression
Well-moderate & nm23=0–3 1 1
Well-moderate & nm23=4–6 1.43 0.76–2.69 0.269 1.61 0.83–3.11 0.160
Poor 1.53 1.05–2.23 0.025 1.77 1.15–2.72 0.009
Surgical stage
I1 1
II 1.46 0.66–3.54 0.316 1.65 0.69–3.93 0.259
III 4.56 2.25–9.27 <0.001 4.75 2.24–10.1 <0.001
IV 5.88 2.76–12.5 <0.001 6.71 2.71–13.6 <0.001
Age at surgery
<60 years 1 1
60–69 years 1.52 1.05–2.23 0.025 1.52 1.05–2.19 0.027
³ 70 years 1.74 1.15–2.65 0.009 1.75 1.14–2.67 0.010
Unkknown 1.46 0.87–2.45 0.148tendency has been completely confirmed by the findings of the
present series, the largest published to date on nm23 expression in
ovarian cancer. Moreover, the statistical analysis of our study
clearly shows that the association with a worse prognosis is stable
over time, and mainly due to an effect on the subgroup of patients
with a relatively better prognosis at the outset, i.e. those with well-
or moderately differentiated tumours at earlier stages of the
disease. Admittedly, our subgroup of early-stage cancers is rela-
tively small (57 patients), if compared to the rest, but this only
reflects the well-known fact that approximately 80% of ovarian
cancer patients are diagnosed at advanced stages. Although the
results obtained by us in this patient group have stood the test of
multivariate analysis, nm23-overexpression being the only prog-
nostic factor to retain statistical significance, they should be defi-
nitely confirmed in a larger series of patients with early-stage
ovarian cancers. For them, a marker defining a high risk subpopu-
lation would be of extreme value. In fact, according to most stan-
dard treatment protocols (Trimbos et al, 1991), there is no need to
further treat most surgically staged patients with a confirmed early
(I to IIA) stage, if their invasive ovarian cancers are well- to
moderately differentiated. Our results, however, would suggest
that precisely among this group of patients, a subgroup overex-
pressing nm23 and a much worse prognosis may be identified,
who might probably benefit from some kind of adjuvant treatment.
For the nm23-H1 gene in human tumours, finally, both allelic
deletion or point mutation seem not to affect prognosis. The only
exception is perhaps childhood neuroblastoma, where overexpres-
sion of the mutant protein together with loss of heterozygosity, has
been associated with a significantly worse prognosis (Leone et al,
1993). Although somatic allelic deletions of the nm23-H1 gene
have been reported for a variety of human cancers, the association
of this finding with a worse prognosis is far from evident in most
cases (Leone et al, 1991b). The same can be said of somatic muta-
tions of the gene, which have indeed been found in a variety of
human tumours, but seem not to play a significant prognostic role,
or give rise to contradictory reports. A particularly striking
example in this respect is colon carcinoma, where some authors
have found a significant correlation between genetic alterations
and a metastatic phenotype (Wang et al, 1993), whereas others
conclude that mutations play a negligible role in this tumour
(Bafico et al, 1993). Fortunately, the results from the few studies
on nm23-H1 that have been performed up to date in ovarian cancer
are rather coincident in that mutations seem to play no significant
role. So, allelic deletions in the long arm of chromosome 17 were
studied by Leary et al (1995) and by Viel et al (1995). Both found
an extremely high frequency of LOH (73–93%) in the tumours
studied, without this having apparently any impact on prognosis or
the metastatic behaviour of the tumours. They conclude that, from
their results, the concept that nm23-H1 might be a suppressor gene
cannot be supported. Although their results differ slightly from the
just reported ones in that they found a lower rate of LOH at the
nm23 locus, the conclusions of Mandai et al (1994) as to the lack
of a suppressor role for nm23 are exactly the same. They searched
for mutations in both nm23-H1 and nm23-H2, and found only one
mutation among 35 invasive ovarian tumours, located in the
nm23-H2 gene. After analysing 60 specimens by means of SSCP
analysis and direct sequencing, we too have been able to identify
only one point mutation, located in the untranslated region of exon
1. According to these data, somatic mutations in the nm23-H1
gene are also a rather uncommon feature in ovarian carcinoma.
All in all, our results, as well as those from the other available
studies on nm23-H1 in human ovarian cancer point towards the
fact that this gene does not function as a classic suppressor gene in
this sort of tumour. If one should judge from the association
between expression of the gene and tumour progession, it seems
rather to act as an oncogene, or at least to be an adjuvant to, or a
byproduct of, oncogenic activation. Since nm23-H2 has been
shown in vitro to initiate transcription of c-myc (Postel et al, 1993),
it is at least theoretically possible that nm23-H1 exerts a similar
action on the same, or a related, oncogene in human ovarian cancer
that could explain its repeated association with a more malignant
phenotype. That it is indeed associated with the development of a
more malignant phenotype in ovarian cancer is strongly suggested
by our results, according to which the negative impact of nm23
expression was most evident in the subgroup of patients hosting
theoretically less aggressive tumours, where it defined a subpopu-
lation with significantly worse outcome, and revealed itself as the
only independent predictor of survival.
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